IL296288B2 - Compositions and methods for treating reperfusion injury or bleeding after recanalization therapy - Google Patents

Compositions and methods for treating reperfusion injury or bleeding after recanalization therapy

Info

Publication number
IL296288B2
IL296288B2 IL296288A IL29628822A IL296288B2 IL 296288 B2 IL296288 B2 IL 296288B2 IL 296288 A IL296288 A IL 296288A IL 29628822 A IL29628822 A IL 29628822A IL 296288 B2 IL296288 B2 IL 296288B2
Authority
IL
Israel
Prior art keywords
composition
tetrafluoro
trifluoromethylbenzylamino
pharmaceutically acceptable
compound
Prior art date
Application number
IL296288A
Other languages
English (en)
Hebrew (he)
Other versions
IL296288B1 (en
IL296288A (en
Original Assignee
Gnt Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gnt Pharma Co Ltd filed Critical Gnt Pharma Co Ltd
Publication of IL296288A publication Critical patent/IL296288A/en
Publication of IL296288B1 publication Critical patent/IL296288B1/en
Publication of IL296288B2 publication Critical patent/IL296288B2/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IL296288A 2020-03-11 2021-03-10 Compositions and methods for treating reperfusion injury or bleeding after recanalization therapy IL296288B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062988187P 2020-03-11 2020-03-11
PCT/IB2021/000136 WO2021181159A1 (en) 2020-03-11 2021-03-10 Compositions and methods for treating reperfusion injury or hemorrhage after recanalization therapy

Publications (3)

Publication Number Publication Date
IL296288A IL296288A (en) 2022-11-01
IL296288B1 IL296288B1 (en) 2024-02-01
IL296288B2 true IL296288B2 (en) 2024-06-01

Family

ID=77665492

Family Applications (2)

Application Number Title Priority Date Filing Date
IL296288A IL296288B2 (en) 2020-03-11 2021-03-10 Compositions and methods for treating reperfusion injury or bleeding after recanalization therapy
IL309923A IL309923A (en) 2020-03-11 2021-03-10 Compositions and methods for treating reperfusion injury or hemorrhage after recanalization therapy

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL309923A IL309923A (en) 2020-03-11 2021-03-10 Compositions and methods for treating reperfusion injury or hemorrhage after recanalization therapy

Country Status (12)

Country Link
US (3) US11826329B2 (https=)
EP (1) EP4117648A4 (https=)
JP (1) JP2023517566A (https=)
KR (1) KR20230010187A (https=)
CN (1) CN115515573A (https=)
AU (1) AU2021233206A1 (https=)
BR (1) BR112022018136A2 (https=)
CA (1) CA3174709A1 (https=)
CO (1) CO2022014343A2 (https=)
IL (2) IL296288B2 (https=)
MX (2) MX2022011214A (https=)
WO (1) WO2021181159A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12285182B2 (en) 2018-10-10 2025-04-29 Innova Vascular, Inc. Devices and methods for removing an embolus
AU2021233206A1 (en) 2020-03-11 2022-10-06 Gnt Pharma Co., Ltd. Compositions and methods for treating reperfusion injury or hemorrhage after recanalization therapy
CN113995723B (zh) * 2020-07-27 2025-02-18 浙江普洛家园药业有限公司 一种索法地尔冻干粉针剂的制备方法及其产品和用途
KR20240142433A (ko) * 2021-12-28 2024-09-30 주식회사 지엔티파마 폐 장애를 치료하기 위한 조성물 및 방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1309703C (zh) * 2002-06-19 2007-04-11 纽若泰克有限公司 四氟苄基衍生物及含有其成分的用于治疗和预防中枢神经系统的急慢性神经变性疾病的药物组合物
KR100522188B1 (ko) * 2003-01-20 2005-10-18 주식회사 뉴로테크 뉴로트로핀에 의해 유도되는 세포괴사 억제 방법
WO2006126825A1 (en) 2005-05-23 2006-11-30 Choongwae Pharma Corporation Composition comprising tetrafluorobenzyl derivatives or salts of thereof for injection
CN101180263B (zh) 2005-05-25 2011-11-02 株式会社中外制药 取代四氟苄基苯胺化合物及其药学可接受的盐的制备方法
KR101523345B1 (ko) 2008-04-28 2015-05-28 주식회사 지엔티파마 재관류 손상의 치료 또는 예방용 약학 조성물
CN102617383A (zh) 2012-03-20 2012-08-01 横店集团家园化工有限公司 索法地尔晶型、制备方法及包含索法地尔晶体的无菌粉末
JP2018502894A (ja) 2015-01-27 2018-02-01 アストラゼネカ アクチボラグ 心筋梗塞の病歴がある患者においてアテローム血栓性イベントを治療または予防する方法
AU2021233206A1 (en) 2020-03-11 2022-10-06 Gnt Pharma Co., Ltd. Compositions and methods for treating reperfusion injury or hemorrhage after recanalization therapy

Also Published As

Publication number Publication date
EP4117648A1 (en) 2023-01-18
EP4117648A4 (en) 2024-05-29
US12433861B2 (en) 2025-10-07
KR20230010187A (ko) 2023-01-18
IL296288B1 (en) 2024-02-01
US20260027076A1 (en) 2026-01-29
US20230390231A1 (en) 2023-12-07
JP2023517566A (ja) 2023-04-26
US20210283080A1 (en) 2021-09-16
IL309923A (en) 2024-03-01
IL296288A (en) 2022-11-01
US11826329B2 (en) 2023-11-28
WO2021181159A1 (en) 2021-09-16
BR112022018136A2 (pt) 2022-10-25
MX2022011214A (es) 2022-10-07
CO2022014343A2 (es) 2023-02-16
AU2021233206A1 (en) 2022-10-06
CN115515573A (zh) 2022-12-23
MX2025012439A (es) 2025-11-03
CA3174709A1 (en) 2021-09-16

Similar Documents

Publication Publication Date Title
US12433861B2 (en) Compositions and methods for treating reperfusion injury or hemorrhage after recanalization therapy
KR101738201B1 (ko) 구토방지제로서의 아미설프라이드의 용도
ES2623503T3 (es) Composiciones para tratar náuseas y vómitos mediados centralmente
EP3013335B1 (en) Combination therapy for the treatment of cancer comprising eribulin and lenvatinib
KR102266014B1 (ko) 안질환 예방 또는 치료용 점안 조성물
ES2249707T3 (es) Tratameinto de combinacion para infarto de miocardio agudo.
JP6051315B2 (ja) 乾癬を処置するためのピドチモドの使用
BR122025026201A2 (pt) Composições que compreendem o composto derivado de tetrafluorobenzila, frascos compreendendo as mesmas, uso terapêutico das mesmas e método para preparar o referido composto
CN117412751A (zh) 用于预防或治疗肺纤维化的药物制剂
KR100869759B1 (ko) 변비형 ibs 예방제/치료제
WO2022199551A1 (en) Dc009 for treating acute ischemic stroke
CN115956079B (zh) 作为用于治疗新生儿缺氧缺血性脑损伤及相关疾病的药物的嘌呤衍生物
KR101768809B1 (ko) 덱사메타손 및 글리벤클라마이드를 포함하는 뇌졸중의 예방 또는 치료용 약학적 조성물
WO2016047662A1 (ja) 脳卒中の治療剤
JP2012136478A (ja) 骨壊死予防及び/又は治療剤
KR20060123329A (ko) 월경 곤란증의 예방 및/또는 치료제
KR20060120204A (ko) 삼출성 중이염의 예방 및/또는 치료제
JPH0369324B2 (https=)